In summary, previous biomarker studies in NENs had suggested that pancreatic NETs and poorly-differentiated NECs were the most promising targets for development of immunotherapy, due to high PD-L1 expression. This evidence concerns the gene CD274 and pancreatic neuroendocrine tumor.